The acquisition of the programmable devices manufacturer Xilinx Corporation by Advanced Micro Devices is likely to be accepted by Chinese regulators. However, this is only a rumour going strong on Social Media and nothing more, so take it with a grain of salt. But let’s dig some more into this hot topic, shall we?
The deal was announced last year by AMD, and the amount for the acquisition was placed at $35 billion; and the deal is expected to close by the end of this year. AMD’s acquisition of Xilinx has already been successfully approved in the United Kingdom and the European Union, and the regulators in the United States have no objections to it by the end of the waiting period earlier this year.
And finally, AMD has to gain the approval of China, and according to recent sources, the approval should occur by the final two months of this year. On the Twitter handle @BitsandChipsEng, who appear quite confident in their information, we see them making allegations that Chinese approval will be arriving soon.
China will not block the AMD-Xilinx merge.
However, many speculations related to this tweet, and many started asking about the truth behind this tweet. But, @BitsandChipsEng went as far as to state that it was confident in the information. This was the sentence which the user posted on Twitter in response to all the doubts:
I’m confident a lot. 100%
As we know, the $35 billion Xilinx deal was announced by AMD late last year and is slated to be completed by the end of this year. The deal will allow AMD to target emerging tech sectors such as artificial intelligence and fifth-generation (5G) cellular technologies. The company will also get a foothold in the field-programmable gate array (FPGA) market.
The European Commission’s approval is as follows:
The Commission assessed possible conglomerate effects and concluded that the transaction does not raise competition concerns in that regard, given the lack of ability and incentive to foreclose rival providers of CPUs and GPUs and the presence of alternative suppliers. The transaction was examined under the normal merger review procedure.
